New Daily Persistent Headache and OnabotulinumtoxinA Therapy

Conclusions Most therapies are unable to break the unremitting course of NDPH. In our investigation, at 1 year (3–4 cycles of onabot treatment), approximately half of the patients treated showed a reduction in headache frequency and approximately 75% demonstrated some improvement in headache severity. Evidence from this small-scale retrospective study suggests that onabot shows strong promise for the treatment of NDPH, which currently is resistant to most therapies, but a randomized controlled study should be the next step in confirmation of this therapy.
Source: Clinical Neuropharmacology - Category: Neurology Tags: Original Articles Source Type: research